Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2014
07/17/2014WO2014109987A1 Mixed disulfide conjugates of thienopyridine compounds and uses thereof
07/17/2014WO2014109863A1 Nutritional compositions containing magnesium threonate and uses thereof
07/17/2014WO2014109862A1 Nutritional compositions containing a neurologic component and uses thereof
07/17/2014WO2014109728A1 Methods and compositions for enchancing transduction efficiency of retroviral vectors
07/17/2014WO2014109725A2 Use of glycyl glutamine against depression
07/17/2014WO2014109632A1 Improvement of cognitive function in preterm infants that are small for gestational age
07/17/2014WO2014108921A2 Carvedilol phosphate solid dispersion
07/17/2014WO2014108899A1 Fluorinated cbd compounds, compositions and uses thereof
07/17/2014WO2014108872A1 Compositions and methods for treating bacterial infections
07/17/2014WO2014108858A1 Fatty acid synthase inhibitors
07/17/2014WO2014108837A1 Combination
07/17/2014WO2014108836A1 Antibacterial oxadiazolone derivatives
07/17/2014WO2014108832A1 Antibacterial oxazolone derivatives
07/17/2014WO2014108820A1 Substituted 2-pyrazinone derivatives as kinase inhibitors
07/17/2014WO2014108809A2 Multiple-component pharmaceutical formulations and methods for their use in treating neuropathology and neurodegeneration caused by traumatic injury
07/17/2014WO2014108808A2 Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
07/17/2014WO2014108807A2 Formulations, methods and procedures for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
07/17/2014WO2014108791A1 Injectable composition containing chlorothiazide
07/17/2014WO2014108759A1 INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA
07/17/2014WO2014108685A1 Pharmaceutical compositions
07/17/2014WO2014108679A1 Benzylamine derivatives
07/17/2014WO2014108571A2 Cancer drug and uses
07/17/2014WO2014108570A1 GALACTOSAMINOGALACTAN COMPRISING α1-4 LINKED GALACTOSE AND α1-4 LINKED N-ACETYLGALACTOSAMINE FOR USE IN THE TREATMENT OF AT LEAST ONE INFLAMMATORY DISEASE
07/17/2014WO2014108569A1 Compositions and methods for treating severe pain
07/17/2014WO2014108529A1 Inhibitory oligonucleotides and their use in therapy
07/17/2014WO2014108520A1 Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
07/17/2014WO2014108452A1 Proteolysis targeting chimeras (protacs) directed to the modulation of the estrogen receptor
07/17/2014WO2014108410A1 Combination therapies for treating ocular disorders
07/17/2014WO2014108408A1 Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease
07/17/2014WO2014108407A1 Pyridone derivatives and their use in the treatment, amelioration or prevention of a viral disease
07/17/2014WO2014108406A1 Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
07/17/2014WO2014108337A1 Pyrazolyl-based carboxamides i as crac channel inhibitors
07/17/2014WO2014108336A1 Pyrazolyl-based carboxamides ii as crac channel inhibitors
07/17/2014WO2014108168A1 Piperidinylcarbazole as antimalarial
07/17/2014WO2014107803A1 Gem-difluorinated c-glycoside compounds as anti-cancer agents
07/17/2014WO2014107794A1 Formulations and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury
07/17/2014WO2014107771A1 Substituted indazole or indole derivatives as in vitro mao-b inhibitors
07/17/2014WO2014081878A3 Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival
07/17/2014WO2014081581A3 Highly loaded amorphous efavirenz composition and process for preparing the same
07/17/2014WO2014081405A3 Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
07/17/2014WO2014079995A3 Novel inhibitor compounds of phosphodiesterase type 10a
07/17/2014WO2014078479A3 INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT)
07/17/2014WO2014076569A3 Controlled release topical testosterone formulations and methods
07/17/2014WO2014075203A8 Nanoparticles with biodegradable and biocompatible polymer plga, loaded with the drug for human use pentoxifylline
07/17/2014WO2014070991A3 Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
07/17/2014WO2014068589A3 Novel process for the preparation of (1-{9-[(4s, 2r, 3r, 5r)-3, 4-dihydroxy-5-(hydroxymethyl) oxolan-2-yl)-6-aminopurin-2-yl} pyrazole-4-yl)-n-methylcarboxamide
07/17/2014WO2014068587A3 An improved process for the synthesis of dabigatran and its intermediates
07/17/2014WO2014062143A3 Combinations of glycopyrrolate and an anticholinergic agent
07/17/2014WO2014047569A3 Product comprising a nicotine-containing material and an anti-cancer agent
07/17/2014WO2014032755A3 Ddr2 inhibitors for the treatment of osteoarthritis
07/17/2014WO2014025905A9 Multi-component formulation for improving neurological function
07/17/2014WO2013182905A3 Mechanism, diagnostic, and treatments for complications of renal failure
07/17/2014WO2013179264A3 Compounds modulating astrocytic release of substances through connexins and pannexins and treatment of psychiatric disorders
07/17/2014WO2013090833A8 Angiotensins for treatment of fibrosis
07/17/2014US20140200654 Drug-delivery endovascular stent and method of forming the same
07/17/2014US20140200531 Mixture for transdermal delivery of low and high molecular weight compounds
07/17/2014US20140200530 Transdermal estrogen device and delivery
07/17/2014US20140200516 Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
07/17/2014US20140200314 Antimicrobial crosslinked polymers containing biomass derived materials
07/17/2014US20140200276 Novel formulation of naproxen
07/17/2014US20140200274 Methods and compositions for treating raynaud's disease
07/17/2014US20140200273 Controlled release pharmaceutical compositions comprising a fumaric acid ester
07/17/2014US20140200272 Controlled release pharmaceutical compositions comprising a fumaric acid ester
07/17/2014US20140200271 Antitussive compositions comprising memantine
07/17/2014US20140200270 Vitamins c and k for treating polycystic diseases
07/17/2014US20140200269 Combination of a Statin and a Taxane for the Treatment of Gastric Cancer
07/17/2014US20140200268 Composition and Method for Treating Dry Eye Syndrome
07/17/2014US20140200267 Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof
07/17/2014US20140200266 Tannin-containing gastrointestinal formulations and methods of use
07/17/2014US20140200260 Methods for determining and inhibiting rheumatoid arthritis associated with the braf oncogene in a subject
07/17/2014US20140200256 Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements
07/17/2014US20140200255 Method for administration
07/17/2014US20140200254 D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders
07/17/2014US20140200252 Crystal forms of saxagliptin
07/17/2014US20140200251 Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties
07/17/2014US20140200250 Anti-cancer agents
07/17/2014US20140200246 Compounds for the treatment of conditions associated with dgat1 activity
07/17/2014US20140200243 Treatment of crohn's disease with laquinimod
07/17/2014US20140200242 Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
07/17/2014US20140200241 Prodrugs for treating microbial infections
07/17/2014US20140200240 Methods for determining patient response to anti-platelet aggregation therapy
07/17/2014US20140200238 Drug treatment of overactive bladder
07/17/2014US20140200237 Compositions of (-)-17-(Cyclobutylmethyl) Morphinan-3,14-Diol
07/17/2014US20140200236 Opioid agonist/antagonist combinations
07/17/2014US20140200234 Adjuvant chemotherapy for anaplastic gliomas
07/17/2014US20140200230 Compositions and methods for inhibiting redox-sensitive gtpases
07/17/2014US20140200226 Anti-malarial compounds from marine natural products
07/17/2014US20140200221 Novel polymorphic forms of 3-(1--6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
07/17/2014US20140200219 Methods of Use of Inhibitors of Phosphodiesterases and Modulators of Nitric Oxide, Reactive Oxygen Species, and Metalloproteinases in the Treatment of Peyronie's Disease, Arteriosclerosis and Other Fibrotic Diseases
07/17/2014US20140200217 Smoothened antagonism for the treatment of hedgehog pathway-related disorders
07/17/2014US20140200211 Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
07/17/2014US20140200210 Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
07/17/2014US20140200204 Combinations of corroles and statins
07/17/2014US20140200203 Topical pharmaceutical compositions
07/17/2014US20140200202 Use of estetrol as emergency contraceptive
07/17/2014US20140200197 Hiv protease inhibitors
07/17/2014US20140200196 Hydrogel Tattoo Protection and Aftercare System
07/17/2014US20140200195 Method for reducing the occurrence on infection in young children
07/17/2014US20140200194 Use of uraria in promoting osteogenesis or providing neuroprotection
07/17/2014US20140200193 Thixotropic biological adhesive for use in internal body cavities
1 ... 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 ... 7860